Vertex Pharmaceuticals Incorporated

Published : May 08th, 2015

FDA questions benefit of cystic fibrosis drug from Vertex

( 0 vote, 0/5 ) Print article
  Article Comments Comment this article Rating Follow Company  
0
Send
0
comment
Keywords :   Pharmaceuticals | Pill | Protein | Ubs | Water |

FDA questions benefit of cystic fibrosis drug from Vertex

WASHINGTON (AP) -- Federal health regulators have questions about the benefits of an experimental combination drug for cystic fibrosis, including whether the addition of a second drug ingredient adds to the pill's effectiveness.

The Food and Drug Administration said in an online review that Vertex Pharmaceuticals' drug improved breathing in patients with the deadly inherited disease, but that the effect was small.

About 30,000 Americans live with cystic fibrosis, a disease that causes sticky mucus buildup in the lungs and other organs, leading to infections, digestive problems and early death. In the 1950s, children with cystic fibrosis seldom survived long enough to complete elementary school. Due to improvements in care, the typical cystic fibrosis patient today can expect to survive into their early 40s, according to the Cystic Fibrosis Foundation.

Vertex's drug, which would be sold under the brand name Orkambi, is the company's follow-up to its breakthrough treatment Kalydeco, which became the first drug to treat the underlying cause of cystic fibrosis in 2012. Orkambi combines Kalydeco with a new drug, lumacaftor.

But FDA scientists say it's unclear that lumacaftor "contributes any added benefit over" Kalydeco alone.

The FDA will ask a panel of outside experts to vote on whether the drug should be approved next Tuesday. The agency is not required to follow the group's recommendations, but it often does.

The apparent lack of added benefit from the new ingredient could complicate Vertex's plans for the drug.

Orkambi is intended to treat the most common form of cystic fibrosis, which affects about 8,500 patients in the U.S. 12 years and older. Kalydeco is only approved for a cluster of rare forms of cystic fibrosis that affect about 2,000 patients 6 years old and up.

In company trials, patients treated with Orkambi for six months reported a 2.5 to 3 percent improvement in lung function, a key measure for cystic fibrosis patients. That improvement was statistically significant, the FDA notes, but "the clinical meaningfulness of the magnitude of the improvement remains to be determined."

Other study measures including body weight and quality of life, as measured via questionnaire, "failed to show substantial evidence of a treatment effect."

FDA scientists questioned whether patients would have seen a similar improvement if treated with the single ingredient in Kalydeco. The government's review notes that Vertex did not test its new drug ingredient alone, making it difficult to assess its benefit.

Despite the FDA's questions, analysts remained confident the FDA would approve the drug.

"There are relatively easy answers to all these questions, hence we have a lot of confidence in a positive vote," said UBS analyst Matthew Roden, in a note to investors.

Vertex said in a statement that its data shows the combination of its two drugs "has a greater effect than either compound alone."

Shares of Vertex Pharmaceuticals Inc. rose $4.95, or 4 percent, to $130 in midday trading Friday. Its shares have more than doubled in price over the past year.

Expectations for Vertex's new drug have been tempered by study results that, while statistically significant, were not as dramatic as those first reported with Kalydeco. The original studies for that drug showed a 10 percent improvement in lung function.

Company officials have pointed out the differences in the forms of the disease targeted by the two drugs. Kalydeco was developed for patients who have a defective protein on their cell walls that fails to properly balance the flow of water and chloride. Orkambi is intended for patients who lack that protein altogether.

The FDA is scheduled to make a decision on Orkambi by July 5.

Vertex's cystic fibrosis drugs grew out of a long-term partnership with the Cystic Fibrosis Foundation. Vertex Pharmaceuticals Incorporated received roughly $120 million in research and funding from the foundation, culminating in the 2012 approval of Kalydeco. The twice-a-day pill had sales of $464 million last year, according to the Cambridge, Massachusetts company.

Last November the Cystic Fibrosis Foundation sold its royalty rights to Kalydeco and related Vertex drugs for $3.3 billion.

Read the rest of the article at sg.finance.yahoo.com

CODE :
Follow and Invest
Add to watch list Add to your portfolio Add or edit a note
Add Alert Add to Watchlists Add to Portfolio Add Note
ProfileMarket
Indicators
VALUE :
Projects & res.
Press
releases
Annual
report
RISK :
Asset profile
Contact Cpy

Vertex Pharma is based in United states of america.

Vertex Pharma is listed in United States of America. Its market capitalisation is US$ 120.0 billions as of today (€ 109.7 billions).

Its stock quote reached its lowest recent point on March 12, 2004 at US$ 10.00, and its highest recent level on October 11, 2024 at US$ 481.71.

Vertex Pharma has 249 070 000 shares outstanding.

Your feedback is appreciated, please leave a comment or rate this article.
Rate : Average note :0 (0 vote) View Top rated
 
Corporate news of
1/27/2016Will Vertex Pharmaceuticals’ Valuation Multiple Improve?
1/26/2016Health Canada Approves PrORKAMBI® (lumacaftor/ivacaftor) - t...
1/26/20165:23 pm Vertex Pharma: Health Canada approves PrORKAMBI
1/26/2016Orkambi: Recent Addition to the Vertex Portfolio
1/26/2016Vertex draws upside bet before earnings
1/25/2016Will Higher Expenses Hurt Vertex's (VRTX) 4Q Earnings?
1/25/2016What Are Wall Street’s Estimates for Vertex Pharmaceuticals?
1/25/2016Vertex Pharmaceuticals: What Are Analysts’ Estimates?
1/20/2016Despite Market and Sector Risks, Why Credit Suisse Now Loves...
1/18/2016Nivalis' N91115 Gets Orphan Drug Status for Cystic Fibrosis
1/15/20164 Biotech Stocks Looking Good this Earnings Season
1/15/2016Vertex Pharmaceuticals (VRTX) Jumps: Stock Moves Up 5.8%
1/5/2016Vertex Announces Upcoming Presentation at the J.P. Morgan He...
12/30/2015Vertex Up 3.2% as Healthcare Sector Continued to Lure Invest...
12/23/2015Vertex Drives IBB’s Large-Caps after Losing for Two Days
12/1/2015Do Hedge Funds Love Intercontinental Exchange Inc (ICE)?
11/27/2015The Zacks Analyst Blog Highlights: BioMarin, Amgen, Vertex, ...
11/23/2015Vertex to Present at the Piper Jaffray Healthcare Conference...
11/23/2015Vertex Appoints Michael J. Parini as Executive Vice Presiden...
11/20/2015Vertex Receives EU Approval for ORKAMBI® (lumacaftor/ivacaft...
11/19/2015Vertex Rises on Two EU Approvals for Drug, Leads XLV’s Large...
11/4/2015Vertex to Present at the Credit Suisse Healthcare Conference...
11/2/2015Health-Care Subpoenas: Should We Start to Worry?
11/2/2015Here’s Why These Four Stocks Are Trending Today
11/2/2015IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces an Inves...
10/31/2015Vertex Pharma receives subpoena from Department of Justice
10/30/2015Law Offices of Howard G. Smith Commences Investigation on Be...
10/30/2015Vertex, Mylan, CVS subpoenaed by federal agencies
10/30/2015SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On...
10/30/2015Nivalis (NVLS): A Surprise in Store this Earnings Season?
10/29/2015Vertex (VRTX) Posts Narrower Q3 Loss, Ups Kalydeco View
10/29/2015Edited Transcript of VRTX earnings conference call or presen...
10/28/2015Vertex Reports Third Quarter 2015 Financial Results
10/28/2015Vertex reports 3Q loss
10/28/20154:07 pm Vertex Pharma beats by $0.14, beats on revs; raises ...
10/27/2015Will Orkambi Help Vertex (VRTX) Post a Lower Loss in Q3?
10/26/2015Vertex and CRISPR Therapeutics Establish Collaboration to Us...
10/26/20158:03 am Vertex Pharma and CRISPR Therapeutics enter strategi...
10/20/2015Oppenheimer Incrementally More Bullish on Gilead, Remains Ca...
10/12/2015Why Energy Stocks Outperformed the Broad Market on October 6
10/9/2015Vertex to Announce Third Quarter 2015 Financial Results on O...
10/8/2015SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Invest...
10/8/2015Vertex's Kalydeco Gets Priority Review for Expanded Use
10/8/2015Vertex Announces Significant Progress in Its Development Eff...
10/7/2015Supplemental New Drug Application for Use of KALYDECO® (ivac...
10/7/2015Supplemental New Drug Application for Use of KALYDECO® (ivac...
10/7/2015Supplemental New Drug Application for Use of KALYDECO® (ivac...
10/7/2015BioMarin Pharmaceutical Takes a Nosedive Last Week
10/1/2015The Zacks Analyst Blog Highlights: Regeneron, Vertex, Gilead...
9/29/2015Regeneron and Mylan End Up in Green for the Week
9/28/2015Why Argus Thinks Now Is the Time to Buy Vertex
9/25/2015IBB Remained Flat Last Week
9/25/2015Vertex Receives CHMP Positive Opinions for ORKAMBI™ (lumacaf...
9/23/2015XBI’s Biotechnology Stocks Rose Week of September 11
9/22/20155 Biotech Stocks Hit Hard by Hillary Clinton's Tweet
9/22/2015Vertex Outperforms XLV on a Year-to-Date Basis
9/21/2015Biotech stocks fall on Clinton vow to fight 'price gouging'
9/18/2015SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Invest...
9/16/2015XLV and XBI Outperform Benchmark Indexes from August 25–31
9/14/2015Amgen And Biogen Lead Short Interest Surge In Biotechs
9/14/2015Vertex Helps Biotechnology Sector Outperform
9/14/2015How Will Vertex Solve Its Falling Revenue Woes?
9/14/2015Vertex Pharma's Orkambi Gives It Huge Potential, Says Barcla...
9/11/2015Vertex and Biogen Outperformd XLV and SPY
9/8/2015Vertex to Present at the Morgan Stanley Healthcare Conferenc...
8/22/2015How Does Vertex Compare to Its Peers?
8/21/2015Vertex Stock Rises after 2Q15 Results Announcement
8/21/2015Will Orkambi Be a Game Changer for Vertex?
8/19/2015Vertex Awards Two Boston Public High School Students the Ver...
8/11/2015What Drove Vertex’s Revenue in 2Q15?
8/11/2015Vertex Reports 2Q15 Revenues of $166.1 Million
8/11/2015What Led Large-Cap Stocks to Outperform Mid and Small Caps?
8/10/2015Key for Investors: How Are Biotech Stocks Trending?
8/10/2015Biotech Stocks Rise Due to a Stable Market: July 31 Week
8/6/2015The Zacks Analyst Blog Highlights: Amgen, Vertex, Regeneron,...
8/4/20153 Potential Huge Takeover Targets in Biotech
7/31/2015Advanced Estimate: US 2Q Gross Domestic Product Expanded by ...
7/30/2015Vertex Posts Wider Y/Y Loss but Raises Kalydeco Outlook - An...
7/30/2015Large-Cap Healthcare Stocks Outperform Small Caps
7/30/2015Edited Transcript of VRTX earnings conference call or presen...
7/29/2015Vertex Reports Second Quarter 2015 Financial Results
7/29/2015Vertex reports 2Q loss
7/28/2015Will Vertex (VRTX) Surprise with a Lower Loss in Q2? - Analy...
7/28/2015CRBP: Warrant Exercise To Provide Sufficient Cash Through 20...
7/24/2015What to Watch in the Week Ahead and on Monday, July 27
7/21/2015How High? The Backlash Over Rising Prescription Drug Prices ...
7/14/2015Vertex to Announce Second Quarter 2015 Financial Results on ...
7/6/2015Vertex Pharma Is 'Hyped,' H.C. Wainwright Sees 35% Downside
7/5/2015Evercore ISI Analyst Gives Highlights From Vertex's Orkambi ...
7/5/20151:46 pm Vertex Pharma confirms FDA approval of its ORKAMBI t...
7/2/2015Business Highlights
7/2/2015ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacafto...
7/2/2015ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacafto...
7/2/2015ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacafto...
7/2/2015ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacafto...
7/2/2015FDA clears drug for leading form of cystic fibrosis
7/2/2015ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacafto...
7/2/2015ADDING MULTIMEDIA FDA Approves ORKAMBI™ (lumacaftor/ivacafto...
7/2/2015Vertex Pharma's lung disorder therapy wins FDA nod
7/2/2015Vertex Shares Leap On FDA Approval For Cystic Fibrosis Combo...
7/2/2015FDA Approves ORKAMBI™ (lumacaftor/ivacaftor) - the First Med...
6/18/2015Sangeeta N. Bhatia, M.D., Ph.D., Joins Vertex Board of Direc...
6/12/2015Edited Transcript of VRTX presentation 11-Jun-15 4:20pm GMT
5/8/2015FDA questions benefit of cystic fibrosis drug from Vertex
4/23/2015Why Vertex Pharmaceuticals (VRTX) Stock Might be a Great Pic...
4/21/2015Gilead's Stock Spikes on Possibility of Vertex Deal
4/21/2015Gilead-Vertex Deal Has 'Low Probability' Of Happening, RBC C...
4/21/2015Bernstein: It's Time For Gilead To Pull The Trigger On This ...
4/17/2015Biotech Investors Shouldn't Miss These Stocks This Earnings ...
4/15/2015Will a New Vertex Drug for Cystic Fibrosis Become a Budget B...
4/9/2015Vertex to Announce First Quarter 2015 Financial Results on A...
4/8/2015Stock Market News for April 08, 2015 - Market News
3/26/2015The Zacks Analyst Blog Highlights: Biogen, Prothena, Vertex,...
3/26/2015One analyst is convinced the biotech stock plunge is 'misgui...
3/24/2015Vertex Falls on Disappointing Kalydeco+VX-661 Combo Data - A...
3/24/2015Vertex Treatment May Have High Risk of Failure, Analyst Sugg...
3/24/2015Stock Market News for March 24, 2015 - Market News
3/23/2015Deutsche Bank: Vertex Pharma's Disappointing VX-661 Trial Re...
3/23/2015Vertex Falls Below Buy Point On Cystic-Fibrosis Drug Data
3/23/2015Pfizer and ImmunoGen are big market movers
3/23/2015ICYMI: Pharmaceutical Stocks Are Moving Big On Monday
Comments closed
 
Latest comment posted for this article
Be the first to comment
Add your comment
NASDAQ (VRTX)
481.71+1.17%
US$ 481.71
10/11 17:00 5.56
1.17%
Prev close Open
476.15 478.53
Low High
475.87 482.89
Year l/h YTD var.
392.81 -  505.78 17.23%
52 week l/h 52 week var.
343.00 -  505.78 30.90%
Volume 1 month var.
893,973 0.639%
Produces
Develops
Explores for
 
 
 
Analyse
Interactive chart Add to compare
Interactive
chart
Print Compare Export
You must be logged in to use the porfolio and watchlists (free)
Top Newsreleases
MOST READ
Annual variation
DateVariationHighLow
202418.39%510.64391.02
202340.90%413.00282.41
202230.17%324.75219.10
2021-6.14%238.26176.36
20206.96%306.08197.47
 
5 years chart
 
3 months chart
 
3 months volume chart
 
 
Mining Company News
Plymouth Minerals LTDPLH.AX
Plymouth Minerals Intersects Further High Grade Potash in Drilling at Banio Potash Project - Plannin
AU$ 0.12-8.00%Trend Power :
Santos(Ngas-Oil)STO.AX
announces expected non-cash impairment
AU$ 7.24+0.76%Trend Power :
OceanaGold(Au)OGC.AX
RELEASES NEW TECHNICAL REPORT FOR THE HAILE GOLD MINE
AU$ 2.20+0.00%Trend Power :
Western Areas NL(Au-Ni-Pl)WSA.AX
Advance Notice - Full Year Results Conference Call
AU$ 3.86+0.00%Trend Power :
Stornoway Diamond(Gems-Au-Ur)SWY.TO
Second Quarter Results
 0.02+100.00%Trend Power :
McEwen Mining(Cu-Le-Zn)MUX
TO ACQUIRE BLACK FOX FROM PRIMERO=C2=A0
US$ 10.06+1.93%Trend Power :
Rentech(Coal-Ngas)RTK
Rentech Announces Results for Second Quarter 2017
US$ 0.20-12.28%Trend Power :
KEFIKEFI.L
Reduced Funding Requirement
GBX 0.57-4.68%Trend Power :
Lupaka Gold Corp.LPK.V
Lupaka Gold Receives First Tranche Under Amended Invicta Financing Agreement
CA$ 0.06+18.18%Trend Power :
Imperial(Ag-Au-Cu)III.TO
Closes Bridge Loan Financing
 2.26+6.10%Trend Power :
Guyana Goldfields(Cu-Zn-Pa)GUY.TO
Reports Second Quarter 2017 Results and Maintains Production Guidance
 1.84+0.00%Trend Power :
Lundin Mining(Ag-Au-Cu)LUN.TO
d Share Capital and Voting Rights for Lundin Mining
 14.59+0.97%Trend Power :
Canarc Res.(Au)CCM.TO
Canarc Reports High Grade Gold in Surface Rock Samples at Fondaway Canyon, Nevada
 0.31+3.33%Trend Power :
Havilah(Cu-Le-Zn)HAV.AX
Q A April 2017 Quarterly Report
 0.20-2.38%Trend Power :
Uranium Res.(Ur)URRE
Commences Lithium Exploration Drilling at the Columbus Basin Project
US$ 6.80-2.86%Trend Power :
Platinum Group Metals(Au-Cu-Gems)PTM.TO
Platinum Group Metals Ltd. Operational and Strategic Process ...
 2.20+4.27%Trend Power :
Devon Energy(Ngas-Oil)DVN
Announces $340 Million of Non-Core Asset Sales
US$ 42.96+0.23%Trend Power :
Precision Drilling(Oil)PD-UN.TO
Announces 2017Second Quarter Financial Results
CA$ 8.66-0.35%Trend Power :
Terramin(Ag-Au-Cu)TZN.AX
2nd Quarter Report
AU$ 0.04+0.00%Trend Power :
Sun Res.(Oil)SUR.AX
Released ASX Announcement: Quarterly Activities Report
AU$ 0.00+0.00%Trend Power :
Take advantage of rising gold stocks
  • Subscribe to our weekly mining market briefing.
  • Receive our research reports on junior mining companies
    with the strongest potential
  • Free service, your email is safe
  • Limited offer, register now !
Go to website.